0001564590-21-000191.txt : 20210105 0001564590-21-000191.hdr.sgml : 20210105 20210104182255 ACCESSION NUMBER: 0001564590-21-000191 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201231 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIODESIX INC CENTRAL INDEX KEY: 0001439725 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 203986492 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39659 FILM NUMBER: 21503211 BUSINESS ADDRESS: STREET 1: 2970 WILDERNESS PLACE STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 303-417-0500 MAIL ADDRESS: STREET 1: 2970 WILDERNESS PLACE STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 8-K 1 bdsx-8k_20201231.htm 8-K bdsx-8k_20201231.htm
false BIODESIX INC 0001439725 0001439725 2020-12-31 2020-12-31



Washington, D.C. 20549



Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

December 31, 2020
Date of Report (Date of earliest event reported) 

Biodesix, Inc.

(Exact Name of Registrant as Specified in Charter) 





(State or other jurisdiction
of incorporation)

File Number)

(I.R.S. Employer
Identification No.)


2970 Wilderness Place, Suite 100

Boulder, Colorado

(Address of Principal Executive Office)


(Zip Code)


Registrant’s telephone number, including area code: (303)  417-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol(s)


Name of each exchange on which registered

Common Stock, par value of $0.001 per share




The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Accounting Officer

Effective December 31, 2020, Ryan H. Siurek was appointed as the Chief Accounting Officer of Biodesix, Inc. (the “Company”). Mr. Siurek will report to Robin Harper Cowie, the Company’s Chief Financial Officer. In this role, Mr. Siurek will function as the Company’s principal accounting officer, and will assume responsibility as principal accounting officer from the Company’s Chief Financial Officer. Ms. Harper Cowie will continue to serve as the Company’s Chief Financial Officer and principal financial officer.

Prior to joining the Company, Mr. Siurek, age 49, previously served as Senior Vice President, Chief Accounting Officer and Controller of Vail Resorts, Inc. from April 2016 to September 2020. From January 2009 to April 2016, Mr. Siurek served as an executive at Sprint Corporation where he held various accounting and finance roles including, Vice President, Controller & Chief Accounting Officer and Vice President, Divisional Chief Financial Officer for the prepaid and wholesale and enterprise solutions divisions. Mr. Siurek earned a BBA in Accounting in 1993 and an MS in Accounting in 1994, both from Texas A&M University, and is a Certified Public Accountant.  Mr. Siurek also serves as a member of the American Institute of Certified Public Accountants (AICPA) Financial Reporting Executive Committee (FinREC), a senior committee focused on financial reporting.

In connection with Mr. Siurek’s employment, Mr. Siurek will be entitled to receive compensation and participate in benefit plans, including equity compensation and annual cash incentive plans, generally available to the Company’s other executives. The plans are described in the Company’s final prospectus dated October 29, 2020, included in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission. Mr. Siurek will also receive an equity award of 45,000 stock options under the Company’s 2020 Equity Incentive Plan (the “Equity Incentive Plan”). The stock options are expected to vest as to 40% of the shares subject to such award on the second anniversary of the appointment date, with the remaining shares vesting in equal monthly installments over the next three years, in each case subject to Mr. Siurek’s continued employment with the Company.

There is no arrangement or understanding pursuant to which Mr. Siurek was selected to serve as an officer of the Company and there are no related party transactions between Mr. Siurek and the Company that would require disclosure under Item 404(a) of Regulation S-K. In addition, there are no family relationships between Mr. Siurek and any director or executive officer of the Company.

Approval of 2020 Equity Incentive Subplan

On December 31, 2020, the Board of Directors of Biodesix, Inc. (the “Company”) approved a new subplan (the “Subplan”) of the Equity Incentive Plan. The Subplan permits designated employees to make an annual election to receive 25%, 50%, 75% or 100% of the annual cash bonus they earn in the following bonus year in the form of a fully-vested nonstatutory stock option award under the Equity Incentive Plan (an “Option”). For each eligible employee, the amount of cash compensation for which an election may be made under the Subplan is limited to such employee’s target annual cash bonus for the applicable bonus year, and may be further limited by a dollar amount set forth in the election form by the Company or the employee.

The number of shares of the Company’s common stock subject to the Option will be determined by multiplying the cash value of the bonus to be received in the form of an Option by four, and then dividing the product of that calculation by the Company’s average share price during the applicable bonus year. The terms and conditions of the Option will be governed by the Equity Incentive Plan and the applicable form of Option award, which award will be reported separately.

The foregoing description is a summary of material terms of the Subplan. The full text of the Subplan will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.



Item 7.01. Regulation FD Disclosure.

On January 4, 2021, the Company issued a press release announcing the appointment of Mr. Siurek as Chief Accounting Officer, as described in Item 5.02 of this Current Report. A copy of the press release announcing the appointment of Mr. Siurek is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:







Press Release issued by Biodesix, Inc. dated January 4, 2021



Cover Page Interactive Data File (embedded within the Inline XBRL document)





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated:  January 4, 2021







/s/ Robin Harper Cowie



Robin Harper Cowie



Chief Financial Officer



EX-99.1 2 bdsx-ex991_42.htm EX-99.1 bdsx-ex991_42.htm

Exhibit 99.1

Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer


Boulder, CO, January 4, 2021 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer.


“I am very pleased to welcome Ryan as our new Chief Accounting Officer. His extensive finance and accounting leadership experience will help Biodesix grow as we enter our next stage of development in 2021 and beyond,” said Ms. Cowie.

Prior to joining the Company, Mr. Siurek served as Senior Vice President, Chief Accounting Officer and Controller of Vail Resorts, Inc. from April 2016 to September 2020. From January 2009 to April 2016, Mr. Siurek served as an executive at Sprint Corporation where he held various accounting and finance roles including Vice President, Controller & Chief Accounting Officer and Vice President, Divisional Chief Financial Officer for the prepaid and wholesale and enterprise solutions divisions. Mr. Siurek earned a BBA & MS in Accounting from Texas A&M University, and is a Certified Public Accountant.  Mr. Siurek also serves as a member of the American Institute of Certified Public Accountants (AICPA) Financial Reporting Executive Committee (FinREC), a senior committee focused on financial reporting.


About Biodesix

Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.




Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks

Exhibit 99.1

and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.


Media Contacts:

Jordona Jackson Smith




EX-101.SCH 3 bdsx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bdsx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 bdsx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 bdsx-8k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001439725 2020-12-31 2020-12-31 false BIODESIX INC 0001439725 8-K 2020-12-31 DE 001-39659 20-3986492 2970 Wilderness Place Suite 100 Boulder CO 80301 (303)  417-0500 false false false false Common Stock, par value of $0.001 per share BDSX NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information
Dec. 31, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 31, 2020
Entity Registrant Name BIODESIX INC
Entity Central Index Key 0001439725
Entity File Number 001-39659
Entity Incorporation State Country Code DE
Entity Tax Identification Number 20-3986492
Entity Address, Address Line One 2970 Wilderness Place
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Boulder
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80301
City Area Code (303) 
Local Phone Number 417-0500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Security 12b Title Common Stock, par value of $0.001 per share
Trading Symbol BDSX
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports bdsx-8k_20201231.htm bdsx-20201231.xsd bdsx-20201231_lab.xml bdsx-20201231_pre.xml bdsx-ex991_42.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdsx-8k_20201231.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bdsx-8k_20201231.htm" ] }, "labelLink": { "local": [ "bdsx-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bdsx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bdsx-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bdsx", "nsuri": "http://biodesix.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "bdsx-8k_20201231.htm", "contextRef": "C_0001439725_20201231_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "bdsx-8k_20201231.htm", "contextRef": "C_0001439725_20201231_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001564590-21-000191-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-000191-xbrl.zip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